India’s pharma market dips to a 2-year low in May – Feedback

The Indian pharmaceuticals market’s growth this May has been the lowest in two years, impacted by a drop in sales of fixed dose combination drugs, fresh price cuts and a lower-than-expected uptake, according to pharmaceutical market research company AIOCD PharmaTrack.

For May, the pharmaceuticals market grew by 7.7% compared to 11.6% during the same month last year, reaching sales of Rs 99,476 crore over a 12-month period based on Moving Annual Total (MAT), according to an agency release. The country’s FDC market dropped 14.6% and is now valued at Rs 196 crore and anti-infectives, derma and respiratory were the worst-hit segments, it added. Fixed dose combination (FDC) drugs are products that have a combination of two or more therapeutic ingredients in a single dose. Indian drug makers were more affected by the drop in volumes in FDCs than multinational drug makers in the country, according to PharmaTrack.

About news

We take care of publishing the latest investment news and highlights for Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *